MedMen Strengthens Balance Sheet, Provides Updated Guidance and Enhances Corporate GovernancePosted by On

LOS ANGELES–()–MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) (“MedMen” or the “Company”), a leading cannabis retailer with operations across the U.S., today announced several financial arrangements and corporate updates that will strengthen the Company’s balance sheet and enhance overall corporate governance. Updates include: 1) the execution of financial agreements (“Financing Plan”), which includes US$37 million in financing; 2) an amendment to certain of the Company’s outstanding debt; 3) an expansion of the Company’s corporate SG&A initiatives through a new round of cost reductions; and 4) enhanced corporate governance with the Company’s co-founder Andrew Modlin granting a limited proxy to Ben Rose, Executive Chairman of the Board with respect to Mr. Modlin’s Class A Super Voting Shares for a period of one year.

“Today’s announcements are a clear indicator of our ability to execute on capital allocation and cost saving initiatives to position MedMen for improved, long-term growth,” said Adam Bierman, MedMen Co-founder and Chief Executive Officer. “Our long-term investors have shown confidence in our strategic direction and industry-leading retail brand. With this strong level of support, we can now further focus management’s attention on maximizing our core assets while also reducing our corporate expenses to achieve positive EBITDA in calendar year 2020.”

“The decision to proxy Andrew’s shares demonstrates the founders’ alignment with shareholder interests and desire to ensure that MedMen is well positioned for future value creation. The Board is supportive of the aggressive steps the Executive team is taking to right size the organization. The asset sales, cost reductions and additional financing will provide MedMen with greater flexibility to execute on its strategy and retain its leadership position in key markets,” said Ben Rose, Executive Chairman of the Board and Chief Investment Officer of Wicklow Capital.

New Financing: Since the Company’s fiscal 2020 first quarter earnings call on November 26, 2019, MedMen has received proceeds or executed term sheets for an additional US$37 million in gross cash proceeds.

Equity Investment: On December 10, 2019, the Company executed a term sheet for its non-brokered offering of subordinate voting shares for aggregate gross proceeds of US$27 million (the “Equity Placement”) at a price per share of US$0.43 with a new strategic investor and an existing investor, Wicklow Capital. The Equity Placement is expected to close on or about December 18, 2019. Shares issued pursuant to the Equity Placement will be subject to a hold period of four months from the closing date. Proceeds raised from the Equity Placement are contemplated to be used to finance working capital requirements and to execute on the Company’s retail footprint expansion plans in its core geographic markets.

Senior Secured Convertible Facility: On October 29, 2019, the Company announced the second amendment (the “GGP Second Amendment”) to the terms of the senior secured convertible credit facility arranged by Gotham Green Partners (the “Facility”). On November 27, 2019, the Company closed on an additional US$10 million under the Facility. Among other changes, the GGP Second Amendment provides greater flexibility to the Company by:

  • Allowing the prepayment at any time following the GGP Second Amendment, in whole or in part, of the then outstanding principal amount together with accrued and unpaid interest and fees;
  • Permitting certain subsidiaries of the Company to incur additional secured debt;
  • Permitting the sale of certain non-core assets; and
  • Removing the senior debt to market capitalization ratio test covenant.

Secured Term Loan Amendment: On December 10, 2019, the Company executed a binding term sheet in respect of certain amendments to the definitive agreements for the US$78 million senior secured term loan (“October 2018 Loan”) with funds managed by Stable Road Capital and its affiliates (“Term Loan Lenders”). Among other amendments, it is contemplated that the terms and conditions of the October 2018 Loan will be amended as follows:

  • The maturity date will be extended from October 1, 2020 to January 31, 2022
  • To reflect current market conditions, the interest rate will be increased from a fixed rate of 7.5% per annum, payable monthly in cash, to a fixed rate of 15.5% per annum, of which 12.0% will be payable monthly in cash based on the outstanding principal and 3.5% will accrue monthly to the principal amount of the debt as a payment-in-kind
  • The Company will cancel the existing warrants issued to the Term Loan Lenders, being 16,211,284 warrants exercisable at US$4.97 per share and 1,023,256 warrants exercisable at US$4.73 per share, and issue to the Term Loan Lenders a total of 40,455,729 warrants exercisable price of US$0.60 per share until December 31, 2022, representing 31% of the loan amount. The warrants to be cancelled represent 100% of the loan amount.

The Company expects to execute definitive agreements for the amendment to the October 2018 Loan on or about December 18, 2019.

Corporate SG&A: The Company is revising its corporate SG&A target to an annualized run-rate of US$65 million, as an update to the 90-day Plan announced on November 15, 2019. The revised target is to be achieved by the end of MedMen’s fiscal third quarter 2020. This represents a US$89 million reduction from its annualized corporate SG&A as of the December 2018 quarter.

The revised corporate SG&A target is based on the realization of headcount and cost reduction initiatives. This week, the Company provided layoff notices to an additional 20% of its corporate-level employees. In total, over the past 30 days, the Company has strategically reduced its corporate headcount by over 40%, representing approximately US$20 million in annual salary-related savings.

Footprint Update:

California: On November 21, 2019, the Company was granted a delivery-only license by the city of Mountain View, California, which granted three delivery-only licenses in total. Mountain View is one of the largest suburbs in California’s Bay Area and is home to several leading technology companies. The Mountain View delivery depot will serve as the Company’s hub for serving the cities in the surrounding areas, which include Palo Alto, Menlo Park and Los Altos.

Illinois: On December 2, 2019, the Company closed on its acquisition of PharmaCann’s Evanston, Illinois location pursuant to the Termination and Release Agreement dated October 7, 2019 entered into between the Company, PharmaCann, LLC and the other parties thereto. The Company began operating the store on December 3, 2019. Evanston is located north of downtown Chicago and is home to Northwestern University. Through the acquisition of Seven Point earlier in the year, the Company also operates a medical dispensary in Oak Park, Illinois. Due to regulatory changes and the termination of the PharmaCann transaction, the Company expects to have a total of four operational recreational stores in Illinois by the end of calendar 2020.

Nevada: On December 5, 2019, the Company announced that MedMen Red, one of MedMen’s in-house lines of cannabis products, was made available in Nevada. MedMen Red flower and pre-rolls are available exclusively at MedMen’s Paradise, Downtown Las Vegas and Spring Valley locations.

Florida: The Company currently operates eight locations across the state of Florida and expects to open one more location in the heart of South Beach Miami in early calendar 2020.

FY 2020 and FY 2021 Financial Guidance: The Company is providing the following guidance, which includes both retail and wholesale revenue, for fiscal 2020 and fiscal 2021 on a market-by-market basis given the contemplated sale of non-core assets. Overall revenue is subject to change based on the Company’s overall footprint during the remainder of its current fiscal year and during fiscal year 2021.

System-Wide

Revenue ($US M)

FY 2020

Guidance

Stores at

EOY

FY 2021

Guidance

Stores at

EOY

California

$140 – $148

14

$260 – $280

20

Nevada

$28 – $30

3

$40 – $45

3

Illinois

$21 – $25

3

$50 – $55

4

Arizona

$16 – $18

3

$20 – $22

3

Florida

$12 – $14

9

$40 – $45

18

New York

$8 – $10

4

$10 – $13

4

Massachusetts

$30 – $40

2

Total

$225 – $245M

36

$450 – $500M

54

The Company anticipates generating positive adjusted EBITDA in the fiscal first quarter 2021, which will end on September 26, 2020, and positive free cash flow in the fiscal third quarter 2021, which will end on March 27th, 2021. The guidance is subject to the following assumptions and risks:

  • Timing and completion of store buildouts and expansions in California, Illinois, Florida, and Massachusetts which will directly impact revenue in FY 2020 and FY 2021
  • Continued quarter-over-quarter same-store sales increases consistent with historical results
  • Obtaining all regulatory approvals for new store openings in California, Illinois and Massachusetts
  • Ability to vertically-integrate in California and Nevada upon full ramp-up of cultivation and production capabilities
  • Continued growth of the Company’s delivery business in California and Nevada
  • Successful execution of announced corporate cost-reduction initiatives
  • Improvement in store-level profitability through improvement in gross margin and payroll optimization

Corporate Governance: Co-founder Andrew Modlin has granted Ben Rose, Executive Chairman of the Board a limited proxy in respect of 815,295 Class A Super Voting Shares, which represents 50% of the total Class A Super Voting Shares for a period of one year. Such proxy may not be used to eliminate or change the rights of such shares…

Original Author Link click here to read complete story.. (c)2018 Business Wire, Inc., All rights reserved.

Business

balancecorporateEnhancesGovernanceGuidancemedmensheetStrengthensupdated

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.